A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy-Reference-Cited by-同舟云学术

A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy

Published:2020-01-01 Issue:1 Volume:12 Page:
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Miao Xiaoniu¹,Luo Yi¹,Huang Xi²,Lee Suki M. Y.³,Yuan Zhijun¹,Tang Yongzhou¹,Chen Liandi¹,Wang Chao¹,Wu Fan¹,Xu Yifeng¹,Jiang Wenchao¹,Gao Wei¹,Song Xuedong¹,Yan Yao¹,Pang Tuling¹,Chen Cheng¹,Zou Yuefeng¹,Fu Weihui¹,Wan Liping¹,Gilbert-Jaramillo Javier⁴,Knight Michael⁴,Tan Tiong Kit⁵,Rijal Pramila⁵,Townsend Alain⁵,Sun Joanne¹,Liu Xiaolin¹,James William⁴,Tsun Andy¹,Xu Yingda¹

Affiliation:

1. New Drug Discovery and Development, Biotheus Inc, Zhuhai, China

2. The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, China

3. New Drug Discovery and Development, Hong Kong Science and Technology Park, China

4. Sir William Dunn School of Pathology, University of Oxford, Oxford, UK

5. Centre for Translational Immunology, Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2020.1804241